Clinical Trials Logo

Adenocarcinoma clinical trials

View clinical trials related to Adenocarcinoma.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT06341725 Terminated - Clinical trials for Pancreatic Adenocarcinoma

EUS Role in Non-metastatic Pancreatic Adenocarcinoma Lymph Nodes Staging

Start date: February 15, 2018
Phase:
Study type: Observational

Aim of the study will be to investigate if Endoscopic Ultrasound (EUS) with elastography can be purposed between the routine staging examinations in patients with pancreatic adenocarcinoma without distant metastasis for the staging of lymph nodes status ("N" in TNM classification) - in RESECTABLE pancreatic cancer the investigators will evaluate the concordance with EUS elastography and histological findings of lymph nodes obtained during surgery, in order to assess the sensibility, specificity and the positive and negative predictive value of EUS with elastography, the disease-free survival, the percentage of metastatic patients and the overall survival (in patients with or without metastatic lymph nodes). - in "BORDERLINE resectable" and UNRESECTABLE non-metastatic ("advanced" locally") disease, the investigators will evaluate if the malignant lymph nodes samples during EUS with elastography and fine needle aspiration (FNA) will be related to a decreased survival. Secondary aim will be to register the prognosis (in terms of survival) of the patients with para-aortic and mediastinal pathological lymph nodes (related to a decreases survival in some series in literature)

NCT ID: NCT05769959 Terminated - Colorectal Cancer Clinical Trials

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

Start date: June 15, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing human leukocyte antigen G (HLA-G).

NCT ID: NCT05687617 Terminated - Gastric Cancer Clinical Trials

Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma.

Start date: December 15, 2022
Phase: Phase 2
Study type: Interventional

Peritoneal disease at initial presentation for patients with gastric adenocarcinoma (GA) is frequent, with 15-31% of patients presenting with peritoneal metastases (PM) at surgical exploration. The prognosis of patients with PM is poor, overall survival (OS) ranging from 8 to 13 months, reinforcing the importance of optimal patient selection before surgical management of GA. Indocyanine Green (ICG) fluorescence imaging for intraoperative detection of PM has been described in recent literature as a useful tool in patients undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancies to increase the detection of PM during surgery. However, the role of ICG for patients with GA, and its role during diagnosic laparoscopy (DL), remain unknown.

NCT ID: NCT05607342 Terminated - Clinical trials for Prostate Adenocarcinoma

Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate

PORT-MAP
Start date: January 3, 2023
Phase: Early Phase 1
Study type: Interventional

To evaluate the effect of Osanetant on testosterone levels in men with prostate cancer within 28 days of therapy.

NCT ID: NCT05546411 Terminated - Pancreatic Cancer Clinical Trials

A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer

Start date: January 6, 2023
Phase: Phase 2
Study type: Interventional

This study is being done to evaluate the safety and efficacy of adding NIS793 to standard of care FOLFIRINOX treatment for pancreatic cancer. The names of the study interventions involved in this study are: - NIS793 - FOLFIRINOX (Folinic acid/Leucovorin, 5-Fluorouracil, Irinotecan, and Oxaliplatin) Other interventions may include: - Chemoradiation Therapy - Surgery

NCT ID: NCT05538624 Terminated - Clinical trials for Fallopian Tube Cancer

A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary

Start date: December 9, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, First-in-Human, Phase 1/2, multicenter study to evaluate the safety and efficacy of a single dose of AVB-001. AVB-001 is an encapsulated cell product engineered to produce native human interleukin-2 (hIL-2). It is delivered intraperitoneally (IP) to patients with high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.

NCT ID: NCT05484011 Terminated - Clinical trials for Metastatic Pancreatic Adenocarcinoma

A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Start date: December 15, 2022
Phase: Phase 1
Study type: Interventional

The primary objective of this maintenance therapy study is to identify the maximum tolerated dose (MTD) and/ or recommended Phase 2 dose (RP2D), and evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) of odetiglucan in combination with CDX-1140 in patients with metastatic PDAC with evidence of response or stable disease following a minimum of 16 and no more than 32 weeks of chemotherapy. Up to 45 patients will be enrolled and dosed (30 patients in Part A and 15 in Part B).

NCT ID: NCT05153408 Terminated - Neoplasms Clinical Trials

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Start date: January 13, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1/2, open-label, first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of BLU-701 as monotherapy or in combination with either osimertinib or platinum-based chemotherapy in patients with EGFRm NSCLC.

NCT ID: NCT05023291 Terminated - Clinical trials for Fluorodeoxyglucose F18

Peroperative Assessment of Tumour Resection Margins Using High-resolution 18F-FDG-PET/CT in Pancreatic Adenocarcinoma

IMA-PANC-CA
Start date: March 30, 2020
Phase: N/A
Study type: Interventional

One of the main risks for recurrence in patients with pancreatic cancer is incomplete surgery of the primary tumor. During the operation, the surgeon bases himself for this on imaging and peroperative vision. Unfortunately, this is not always sufficient and it is sometimes determined after surgery that the cutting edges are not free of tumor cells. Research has already shown that there is a significantly better survival when a margin of at least 1 mm is maintained between the macroscopic tumor and the cut surface. It is therefore important to remove the tumor as completely as possible without the risk of residual tissue and with a sufficiently wide margin. The only method that can currently be used to determine during surgery if the tumor has been completely removed is to use "frozen sections". With a frozen section, the surgical piece is sent to the pathology department during the operation, where sections are taken from the edges. These are frozen in nitrogen and immediately viewed by a pathologist. If the cut edge is positive, this will be passed on to the surgeon who will take a wider resection if possible. Unfortunately, this method is time consuming and labor intensive. The evaluation of these cut edges on frozen section is not easy and requires a lot of experience. The percentage of false negative reviews for frozen section is not high, but it is true that it is not non-existent either. In addition, it is not possible to evaluate all cleavage surfaces peroperatively. This is currently happening for the distal pancreatic cutting edge and the bile duct cutting edge, but not, for example, for the posterior pancreatic surface and for the surface of the groove in which the superior mesenteric vein runs. The use of peroperative imaging in the form of 18F-FDG PET-CT scan of the tumor would be a clear asset for this. This would not only be faster than frozen sections, but also provide a full 3-dimensional image of the extracted specimen, which may provide more insights than 2D frozen sections. The ultimate goal of this study is to bring the high resolution PET-CT system into the operating theater. For example, during the operation, in the operating theater itself, it could be determined where residual tumor tissue would be present and then performed a wider resection in order to avoid a positive margin status.

NCT ID: NCT05012397 Terminated - Gastric Cancer Clinical Trials

Milademetan in Advanced/Metastatic Solid Tumors

Start date: November 1, 2021
Phase: Phase 2
Study type: Interventional

Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that exhibit wild-type (WT) TP53 and MDM2 copy number (CN) ≥ 8 using prespecified biomarker criteria.